ADMIRE

Serial Number 98066290
809

Registration Progress

Application Filed
Jun 30, 2023
Under Examination
Jan 9, 2024
Approved for Publication
Nov 14, 2023
Published for Opposition
Nov 14, 2023
Registered

Trademark Image

ADMIRE

Basic Information

Serial Number
98066290
Filing Date
June 30, 2023
Published for Opposition
November 14, 2023
Drawing Code
3

Status Summary

Current Status
Active
Status Code
809
Status Date
Apr 22, 2025
Application
Pending
Classes
042

Rights Holder

Abbvie Inc.

03
Address
V377/AP34-2
1 N. Waukegan Road
North Chicago, IL 60064

Ownership History

Abbvie Inc.

Original Applicant
03
North Chicago, IL

Abbvie Inc.

Owner at Publication
03
North Chicago, IL

Legal Representation

Attorney
Cheryl A. Withycombe

USPTO Deadlines

All Deadlines Cleared

All 5 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

36 events
Date Code Type Description Documents
Apr 22, 2025 GNFN O NOTIFICATION OF FINAL REFUSAL EMAILED Loading...
Apr 22, 2025 GNFR O FINAL REFUSAL E-MAILED Loading...
Apr 22, 2025 CNFR W SU - FINAL REFUSAL - WRITTEN Loading...
Apr 4, 2025 ALIE A ASSIGNED TO LIE Loading...
Apr 4, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Apr 4, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Mar 19, 2025 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Dec 18, 2024 XELG O APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Loading...
Dec 18, 2024 XELR I APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Loading...
Sep 19, 2024 GNRT O NON-FINAL ACTION E-MAILED Loading...
Sep 19, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Sep 19, 2024 CNRT W SU - NON-FINAL ACTION - WRITTEN Loading...
Sep 16, 2024 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Sep 16, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Sep 16, 2024 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Sep 16, 2024 EX1G S SOU EXTENSION 1 GRANTED Loading...
Jul 14, 2024 TPEX I SOU EXTENSION RECEIVED WITH TEAS PETITION Loading...
Jul 14, 2024 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Jul 14, 2024 PETG O PETITION TO REVIVE-GRANTED Loading...
Jul 14, 2024 PROA I TEAS PETITION TO REVIVE RECEIVED Loading...
Jul 14, 2024 NREV E NOTICE OF REVIVAL - E-MAILED Loading...
Jul 14, 2024 IUAF S USE AMENDMENT FILED Loading...
Jul 14, 2024 EXT1 S SOU EXTENSION 1 FILED Loading...
Jan 9, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Nov 14, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
Nov 14, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Oct 25, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Oct 9, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Oct 9, 2023 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Oct 9, 2023 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Oct 9, 2023 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Oct 9, 2023 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Oct 5, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 2, 2023 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Aug 1, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jul 4, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 042
providing information about medical clinical trials, namely, information in the field of improving diversity and inclusion in clinical research studies and clinical trials.
First Use Anywhere: Jan 31, 2023
First Use in Commerce: Jan 31, 2023

Additional Information

Design Mark
The mark consists of The word "admire" with stylized parenthesis on both sides that appear as half circle shapes.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
042